PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
22.78%
Cost increase while AGEN reduces costs. John Neff would investigate competitive disadvantage.
-30.37%
Gross profit decline while AGEN shows 9.64% growth. Joel Greenblatt would examine competitive position.
-30.37%
Margin decline while AGEN shows 16.96% expansion. Joel Greenblatt would examine competitive position.
45.24%
R&D growth less than half of AGEN's 139.80%. David Dodd would verify if efficiency advantage is sustainable.
-4.95%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
24.69%
Operating expenses growth while AGEN reduces costs. John Neff would investigate differences.
24.69%
Total costs growth while AGEN reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
22.78%
D&A growth above 1.5x AGEN's 1.01%. Michael Burry would check for excessive investment.
-24.88%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
-24.88%
Both companies show margin pressure. Martin Whitman would check industry conditions.
-24.83%
Operating income decline while AGEN shows 6.55% growth. Joel Greenblatt would examine position.
-24.83%
Operating margin decline while AGEN shows 14.13% growth. Joel Greenblatt would examine position.
291.57%
Other expenses growth while AGEN reduces costs. John Neff would investigate differences.
-21.98%
Both companies show declining income. Martin Whitman would check industry conditions.
-21.98%
Both companies show margin pressure. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-17.79%
Both companies show declining income. Martin Whitman would check industry conditions.
-17.79%
Both companies show margin pressure. Martin Whitman would check industry conditions.
-12.12%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-9.09%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
5.06%
Share count reduction below 50% of AGEN's 4.90%. Michael Burry would check for concerns.
6.04%
Diluted share reduction below 50% of AGEN's 3.55%. Michael Burry would check for concerns.